Graphene-Induced Transdifferentiation of Cancer Stem Cells as a Therapeutic Strategy against Glioblastoma
Source abstract
Abstract
Glioblastoma (GBM) is an extremely malignant tumor of the central nervous system, characterized by low response to treatments and reoccurrence. This therapeutic resistance is believed to arise mostly from the presence of a subpopulation of tumorigenic stem cells, known as cancer stem cells (CSCs). In addition, the surrounding microenvironment is known to maintain CSCs, thus supporting tumor development and aggressiveness. This review focuses on a therapeutic strategy involving the stem cell trans-differentiating ability of graphene and its derivatives. Graphene distinguishes itself from other carbon-based nanomaterials due to an array of properties that makes it suitable for many purposes, from bioengineering to biomedical applications. Studies have shown that graphene is able to promote and direct the differentiation of CSCs. In addition, potential usage of graphene in GBM treatment represents a challenge in respect to its administration method. The present review also provides a general outlook of the potential side effects (e.g., cell toxicity) that graphene could have. Overall, this report discusses certain graphene-based therapeutic strategies targeting CSCs, which can be considered as prospective effective GBM treatments.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Graphene and Nanomaterials Applications · Graphene research and applications · Carbon and Quantum Dots Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
University College London, Queen Square Institute of Neurology, London WC1N 3BG, U.K.
Department of Physics and Astronomy, School of Mathematical and Physical Sciences, University of Sussex, Brighton BN1 9QG, U.K.
Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton BN1 9QG, U.K.
Funding
Action Against Cancer · Searle Memorial Charitable Trust · Rothschild Foundation · Bernard Sunley Foundation · Colin McDavid Family Trust
References (95)
Show source-provided references
1. 10.1101/gad.261982.11510.1101/gad.261982.115 ↗
2. 10.1016/j.ccr.2009.12.02010.1016/j.ccr.2009.12.020 ↗
3. 10.1038/s42003-019-0560-x10.1038/s42003-019-0560-x ↗
4. 10.3389/fonc.2015.0015910.3389/fonc.2015.00159 ↗
5. 10.1093/jnen/nlw06810.1093/jnen/nlw068 ↗
6. 10.1093/neuonc/noy12010.1093/neuonc/noy120 ↗
7. 10.3389/fphar.2016.0047710.3389/fphar.2016.00477 ↗
8. 10.1371/journal.pone.012545410.1371/journal.pone.0125454 ↗
9. 10.18632/oncotarget.334810.18632/oncotarget.3348 ↗
10. 10.1016/j.ccr.2006.11.02010.1016/j.ccr.2006.11.020 ↗
11. 10.1016/j.cell.2019.06.02410.1016/j.cell.2019.06.024 ↗
12. 10.18632/oncotarget.927510.18632/oncotarget.9275 ↗
13. 10.1016/j.drup.2018.03.00310.1016/j.drup.2018.03.003 ↗
14. 10.1016/j.canlet.2017.12.00510.1016/j.canlet.2017.12.005 ↗
15. 10.1038/nature0534910.1038/nature05349 ↗
16. 10.1093/carcin/bgx07010.1093/carcin/bgx070 ↗
17. 10.3390/genes902010510.3390/genes9020105 ↗
18. 10.1158/0008-5472.CAN-19-122910.1158/0008-5472.CAN-19-1229 ↗
19. 10.1101/gad.321968.11810.1101/gad.321968.118 ↗
20. 10.1158/0008-5472.CAN-06-418010.1158/0008-5472.CAN-06-4180 ↗
21. 10.4161/cbt.2200010.4161/cbt.22000 ↗
22. 10.1172/JCI3440110.1172/JCI34401 ↗
23. 10.1186/s12885-016-2774-310.1186/s12885-016-2774-3 ↗
24. 10.1371/journal.pone.017279110.1371/journal.pone.0172791 ↗
25. 10.2176/nmc.ra.2018-014110.2176/nmc.ra.2018-0141 ↗
26. 10.7150/thno.3380010.7150/thno.33800 ↗
27. 10.21037/atm.2017.03.3910.21037/atm.2017.03.39 ↗
28. 10.1016/j.ccell.2017.02.00910.1016/j.ccell.2017.02.009 ↗
29. 10.1002/glia.2352010.1002/glia.23520 ↗
30. 10.1038/s41598-019-45535-y10.1038/s41598-019-45535-y ↗
31. 10.1038/s41388-019-0903-610.1038/s41388-019-0903-6 ↗
32. 10.1007/s12017-014-8324-810.1007/s12017-014-8324-8 ↗
33. 10.1016/j.molmed.2017.01.00210.1016/j.molmed.2017.01.002 ↗
34. 10.1186/s12943-018-0878-x10.1186/s12943-018-0878-x ↗
35. 10.3389/fmats.2017.0004510.3389/fmats.2017.00045 ↗
36. 10.3390/cancers202085910.3390/cancers2020859 ↗
37. 10.1186/s12885-015-1086-310.1186/s12885-015-1086-3 ↗
38. 10.1371/journal.pone.001244510.1371/journal.pone.0012445 ↗
39. 10.1016/j.ccr.2006.03.03010.1016/j.ccr.2006.03.030 ↗
40. 10.1016/j.celrep.2016.12.03710.1016/j.celrep.2016.12.037 ↗
41. 10.3892/ol.2019.1069110.3892/ol.2019.10691 ↗
42. 10.3390/md1709052510.3390/md17090525 ↗
43. 10.1038/nmat226910.1038/nmat2269 ↗
44. 10.3389/fmats.2018.0002710.3389/fmats.2018.00027 ↗
45. 10.1002/jbm.a.3660310.1002/jbm.a.36603 ↗
46. 10.1177/088532821875571110.1177/0885328218755711 ↗
47. 10.1002/mabi.20197000310.1002/mabi.201970003 ↗
48. 10.3390/molecules2303055310.3390/molecules23030553 ↗
49. 10.1016/j.biomaterials.2013.12.00110.1016/j.biomaterials.2013.12.001 ↗
50. 10.3390/ijms1812254910.3390/ijms18122549 ↗
51. 10.1016/j.msec.2018.01.00410.1016/j.msec.2018.01.004 ↗
52. 10.1021/nn202190c10.1021/nn202190c ↗
53. 10.1007/s13770-013-0384-610.1007/s13770-013-0384-6 ↗
54. 10.3390/molecules2404065810.3390/molecules24040658 ↗
55. 10.1038/s41598-017-06051-z10.1038/s41598-017-06051-z ↗
56. 10.1021/acsami.6b1230510.1021/acsami.6b12305 ↗
57. 10.1016/j.biomaterials.2017.10.00410.1016/j.biomaterials.2017.10.004 ↗
58. 10.4172/2324-9110.100012310.4172/2324-9110.1000123 ↗
59. 10.1016/j.brainres.2007.08.05010.1016/j.brainres.2007.08.050 ↗
60. 10.1016/j.addr.2014.08.01210.1016/j.addr.2014.08.012 ↗
61. 10.1038/srep0160410.1038/srep01604 ↗
62. 10.1021/nn900694t10.1021/nn900694t ↗
63. 10.1021/nn100636810.1021/nn1006368 ↗
64. 10.1039/B917103G10.1039/B917103G ↗
65. 10.1016/j.ejpb.2016.04.01510.1016/j.ejpb.2016.04.015 ↗
66. 10.2217/nnm-2018-026910.2217/nnm-2018-0269 ↗
67. 10.1016/j.biomaterials.2011.09.07110.1016/j.biomaterials.2011.09.071 ↗
68. 10.3389/fnsys.2018.0001210.3389/fnsys.2018.00012 ↗
69. 10.1073/pnas.122227611010.1073/pnas.1222276110 ↗
70. 10.1016/j.biomaterials.2016.03.03610.1016/j.biomaterials.2016.03.036 ↗
71. 10.1021/ar300199e10.1021/ar300199e ↗
72. 10.1016/j.biomaterials.2015.07.06010.1016/j.biomaterials.2015.07.060 ↗
73. 10.1016/j.biomaterials.2012.11.05210.1016/j.biomaterials.2012.11.052 ↗
74. 10.2217/nnm.13.19710.2217/nnm.13.197 ↗
75. 10.1038/cr.2013.7510.1038/cr.2013.75 ↗
76. 10.1016/j.stem.2010.01.00110.1016/j.stem.2010.01.001 ↗
77. 10.1016/S0070-2153(10)92012-710.1016/S0070-2153(10)92012-7 ↗
78. 10.2147/IJN.S14619310.2147/IJN.S146193 ↗
79. 10.3390/ijms1912393910.3390/ijms19123939 ↗
80. 10.2147/IJN.S6249710.2147/IJN.S62497 ↗
81. 10.3390/ijms16102521410.3390/ijms161025214 ↗
82. 10.1098/rsfs.2018.000210.1098/rsfs.2018.0002 ↗
83. 10.1186/s12867-018-0119-210.1186/s12867-018-0119-2 ↗
84. 10.3390/ijms2003065010.3390/ijms20030650 ↗
85. 10.1016/j.biomaterials.2012.02.02110.1016/j.biomaterials.2012.02.021 ↗
86. 10.1021/nn300172t10.1021/nn300172t ↗
87. 10.1002/smll.20110239310.1002/smll.201102393 ↗
88. 10.1038/srep0258410.1038/srep02584 ↗
89. 10.1002/smll.20130323410.1002/smll.201303234 ↗
90. 10.1002/smll.20090168010.1002/smll.200901680 ↗
91. 10.1155/2014/86926910.1155/2014/869269 ↗
92. 10.1016/j.biomaterials.2014.04.05710.1016/j.biomaterials.2014.04.057 ↗
93. 10.1016/j.biomaterials.2014.04.06610.1016/j.biomaterials.2014.04.066 ↗
94. 10.1016/j.colsurfb.2015.03.02210.1016/j.colsurfb.2015.03.022 ↗
95. 10.1016/j.biomaterials.2010.10.03010.1016/j.biomaterials.2010.10.030 ↗